On track to initiate EscharEx® Phase III study in fourth quarter 2023NexoBrid® U.S. launch expected in early third quarter 2023Cash of over $57 million; Operating cash runway through. | May 30, 2023
Conference Call and Webcast Scheduled for Tuesday, May 30th at 8:30 am Eastern TimeYAVNE, Israel, May 12, 2023 MediWound Ltd. , the global leader in next-generation enzymatic therapeutics for. | May 12, 2023
Appoints Barry Wolfenson, as Executive Vice President of Strategy and Corporate Development Appoints Alicia Torrenova, as Vice President of European Operations Both bring extensive leadership. | March 6, 2023
YAVNE, Israel, Sept. 12, 2022 MediWound Ltd. , a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration,. | September 12, 2022